The dream of a disease free world

Our approach with OmniCART aims to treat a wide range of cancers by redesigning immune cells to fight them.

Cancer is a disease caused due to a mutation in the DNA within cells that causes them to multiply at an abnormal rate and is one of the leading causes of death in the world. We are currently developing OmniCART to treat lung cancer, prostate cancer, breast cancer, oral cancer and brain tumours. They have been chosen based on the criteria that they either do not currently have effective clinical solutions, have a very rigorous impact on patient life and contribute significantly to the worldwide cancer burden.

Current Line of Treatment



Monoclonal Antibodies
  • High chance of reoccurrence
  • Long duration therapy


  • Not targeted
  • Serious side effects
  • Painful


  • Invasive
  • Selective use cases

Significant Worldwide Burden

Annual Cases


6.9 m

OmniCART is a next-generation allogenic (universal) CAR T-cell therapy where human cells are redesigned to fight cancer cells. The biggest challenge in allogenic CAR T-cell therapy is the graft-vs-host response that comes from foreign T cells. At Micro, we use CRISPR to knock-out genes from the T-cells that are responsible for graft-vs-host disease, hence making them allogenic. Furthermore, we also use CRISPR to reduce T cell apoptosis and to improve their effectiveness.

Additionally, based on the type of cancer, we make several further CRISPR edits to make our therapy more potent for each of the five cancer types.

Check out some of the other next-generation living therapeutics that are being developed by Micro CRISPR.